Insilico Medicine said it advanced its AI drug target discovery framework by integrating Target Identification Pro (TargetPro) with Target Identification Benchmark (TargetBench 1.0) into a validated unified system. The update is positioned as an effort to improve accuracy, reliability, and scalability of early discovery outputs. The company’s messaging emphasizes how prediction is coupled with benchmarking, a structure designed to reduce false positives and improve reproducibility across targets and modalities. For drug developers, the key question will be how consistently the platform identifies druggable targets that translate into hit-series and lead-optimization candidates. Industry watchers will also consider how these platform steps may integrate with partner pipelines and whether benchmark-driven improvements translate into measurable efficiency gains in preclinical timelines.